超微量肝素对重症新生儿硬肿症的治疗研究

ULTRAMICROHEPARIN FOR THE TREATMENT OF SEVERE SCLERODERMA NEONATORUM

该文应用超微量肝素对重症新生儿硬肿症进行治疗研究，资料表明：治疗组临床症状：体温、哭声低下或不哭、尿少或无尿、呼吸困难、肺出血恢复正常时间以及皮肤硬肿、皮肤苍白或青紫、四肢或全身冰冷、心率增快或减慢以及低血压恢复正常时间均比对照组为早（Ｐ＜０．０１）；吮乳困难与肢体活动恢复正常时间、脉细弱恢复正常时间也均比对照组早（Ｐ＜０．０５）。治疗组血生化检测高钠血症、代谢性酸中毒以及高尿素氮质血症恢复正常时间均比对照组为早（Ｐ＜０．００５）；高钾血症与低血糖症恢复正常时间也比对照组为早（Ｐ＜０．０２）。超微量肝素疗法使用简便、经济、不需凝血检测监护、且安全无副作用、临床易于推广，为今后研究重症新生儿硬肿症提供新的治疗措施。

Eighty cases of scleroderma neonatorum (41 males and 39 females,the ages are from one day to seven days), were randomly divided into two groups:the therapeutic group (40 cases) and the control group(40 cases).On the basis of general treatment,the patients in therapeutic group were used heparin,1U/kg (heparin 1mg=125U),slowly injected under the abdominal skin,One time an hour,one to three days as a course of treatment.In the therapeutic group and control group,the time of cure rate,deathrate,hypothermia,loss of vioce,dysphagia,Oliguria or anuria,pulmonary-bleed,scleredema,hypernatremia,hyperkaliemia,metabolic acidosis,uremia and hypoglycemia returning to normal are respectively 87.50 % Vs 67.50% (P<0.05),12.50% Vs 32.50% (P<0.05),1.59±0.31d Vs 1.91±0.34d(P<0.001),1.24±0.33d Vs 1.57±0.45d (P<0.002),2.16±0.54d VS 2.46±0.44d (P<0.02),2.07±0.35d Vs 2.57±0.41d (P<0.005),2.29±0.25d VS 2.82±0.25d (P<0.01),2.44±0.43d Vs 2.87±0.33d (P<0.001),1.34±0.38d Vs 1.74±0.37d (P<0.001),1.55±0.44d Vs 1.90±0.54d (P<0.02),1.33±0.30d Vs 1.61±0.35d (P<0.002),1.52±0.36d Vs 1.82±0.38d (P<0.005)and 1.50±0.34d Vs 1.75±0.42d (P<0.02).The result showed that ultramicroheparin is effective to treat severe scleredema neonatorum.